Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and some of the latest approaches that strive to overcome these hurdles. Learn about recent efforts...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.
An mRNA vaccine with immunotherapy may lower recurrence in melanoma, and active surveillance for prostate cancer has increased in the Veterans Affairs health system over the last two decades.
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years. Here, we provide an overview of how this...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution, sex differences in immune responses, the discovery of a new subset of cells that promote...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More